 Shares of Vir Biotechnology Inc. VIR, 15.99 were up 12.8 in premarket trading on Wednesday, the day after it was announced that the stock will join the SP SmallCap 600 SML, -0.20 , effective April 4. The company is led by George Scangos, the former CEO of Biogen Inc. BIIB, -0.06 ; it has one authorized therapy, the COVID-19 monoclonal antibody, sotrovimab. 